Why the study?
Thromboprophylaxis is not routinely recommended for ambulatory cancer patients receiving chemotherapy, making the identification of patients at risk of cancer-associated thrombosis who would benefit most from anticoagulation critical.
Does thromboprophylaxis reduce venous thromboembolism in ambulatory patients with cancer?
Does thromboprophylaxis reduce venous thromboembolism in ambulatory patients with cancer?
Thromboprophylaxis with LMWH or DOACs can reduce VTE risk in high-risk ambulatory cancer patients, emphasizing the need for individualized risk assessment using tools like the Khorana score.
May support considering DOACs in selected high-risk ambulatory patients; leaves open refined risk models before wider use.
Patients with cancer are at high risk of venous thromboembolic events, and this risk can be further increased in patients with certain cancer types and by cancer treatments. Guidelines on the prevention of cancer-associated thrombosis (CAT) recommend thromboprophylaxis for hospitalised patients; however, this is not routinely recommended for ambulatory patients receiving chemotherapy and is limited to specified high-risk patients. Identification of the ambulatory patients at risk of CAT who would most benefit from anticoagulant therapy is therefore critical to reduce the incidence of this complication. For patients receiving thromboprophylaxis for CAT, treatment options include low molecular weight heparin, acetylsalicylic acid, warfarin or direct oral anticoagulants (apixaban or rivaroxaban), dependent on the cancer type and cancer treatment regimen. This review discusses emerging clinical trial data and their potential clinical impact.
No takes yet. Share an insight, caveat, or question.
Khorana et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: